

## CombiGene's research is recognized internationally after careful scientific review

Associate Professor David Woldbye, one of CombiGene's scientific founders, presents in a new peer-reviewed article in *Frontiers in Molecular Neuroscience* the outcome of CombiGene's preclinical pharmacokinetic study, the company's preclinical learning and memory study and the preclinical tropism study. All studies have been conducted within the framework of the epilepsy project CGO1.

The pharmacokinetic study indicates that one can expect NPY and Y2, the active substances encoded by CGO1, to have a long-term expression in the human brain. The results of the pharmacokinetic study provide important knowledge to plan the future safety studies (toxicology and biodistribution) in an optimal way. The knowledge from the pharmacokinetic study will also be a central part of the knowledge pool when the first study in humans is designed.

The results of the learning and memory study show that NPY and Y2 do not have a significant negative impact on cognitive functions. Associate Professor Woldbye has previously commented on the study results as follows: *"The results of previous academic studies on the impact of NPY on memory and learning are ambiguous. It is therefore good that we can now, with CGO1, show that we do not affect memory and learning in animals when we inject CGO1 into one of the brain's two hippocampi, just as we intend to do in humans."*

The conducted tropism study shows that CGO1 occurs as expected, i.e., the drug candidate is absorbed into the nerve cells of the hippocampus, but not in the supporting cells, the so-called glial cells.

The results of the study are very encouraging as they provide further confirmation that CGO1 reaches the brain cells as intended.

The results, presented in *Frontiers in Molecular Neuroscience*, have been reviewed by researchers and experts in the field and data from the studies have been rigorously assessed, ensuring scientific quality.

### Facts about the article

Journal: *Frontiers in Molecular Neuroscience*

Title: Gene therapy vector encoding neuropeptide Y and its receptor Y2 for future treatment of epilepsy: preclinical data in rats

Link: <https://bit.ly/2LaK53n>

Authors: Julia Alicja Szczygiel, Kira Iben Danielsen, Esbjörn Melin, Søren Hofman Rosenkranz, Stanislava Pankratova, Annika Ericsson, Karin Agerman, Merab Kokaia, David Paul Drucker Woldbye



CombiGene's lead project CGO1 has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 823282

### About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, [info@fnca.se](mailto:info@fnca.se).

### For further information:

CombiGene AB (publ)  
Jan Nilsson, CEO  
Tel: +46 (0)704 66 31 63  
[jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

Bert Junno, Chairman of the board  
Tel: +46 (0) 70 777 22 09  
[bert.junno@combigene.com](mailto:bert.junno@combigene.com)

**Please read *INGENEIOUS*, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. *INGENEIOUS* and press releases are available at [www.combigene.com](http://www.combigene.com)**